Search Orphan Drug Designations and Approvals
-
Generic Name: | vibostolimab and pembrolizumab |
---|---|
Date Designated: | 11/08/2022 |
Orphan Designation: | Treatment of Small Cell Lung Cancer (SCLC) |
Orphan Designation Status: | Designated |
FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
Sponsor: |
Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc. 126 East Lincoln Ave P.O.Box 2000 Rahway, New Jersey 07065 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-